WO2007127475A3 - Pyridazines for demyelinating diseases and neuropathic pain - Google Patents

Pyridazines for demyelinating diseases and neuropathic pain Download PDF

Info

Publication number
WO2007127475A3
WO2007127475A3 PCT/US2007/010464 US2007010464W WO2007127475A3 WO 2007127475 A3 WO2007127475 A3 WO 2007127475A3 US 2007010464 W US2007010464 W US 2007010464W WO 2007127475 A3 WO2007127475 A3 WO 2007127475A3
Authority
WO
WIPO (PCT)
Prior art keywords
demyelinating diseases
neuropathic pain
compositions
pyridazines
pain
Prior art date
Application number
PCT/US2007/010464
Other languages
French (fr)
Other versions
WO2007127475A2 (en
Inventor
Martin Watterson
Eldik Linda Van
Wenhui Hu Ph D
Original Assignee
Univ Northwestern
Martin Watterson
Eldik Linda Van
Wenhui Hu Ph D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern, Martin Watterson, Eldik Linda Van, Wenhui Hu Ph D filed Critical Univ Northwestern
Publication of WO2007127475A2 publication Critical patent/WO2007127475A2/en
Publication of WO2007127475A3 publication Critical patent/WO2007127475A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compositions and methods for treating patients with Demyelinating Diseases and Conditions including Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compositions and methods may also be used for Stroke Rehabilitation and the treatment of pain disorders including Neuropathic Pain and Chemokine-Induced Pain. The compositions comprise one or more pyridazine compounds having a pyridazinyl radical pendant with an aryl or substituted aryl, a heteroaryl or substituted heteroaryl.
PCT/US2007/010464 2006-04-28 2007-04-27 Pyridazines for demyelinating diseases and neuropathic pain WO2007127475A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79634306P 2006-04-28 2006-04-28
US60/796,343 2006-04-28

Publications (2)

Publication Number Publication Date
WO2007127475A2 WO2007127475A2 (en) 2007-11-08
WO2007127475A3 true WO2007127475A3 (en) 2008-11-06

Family

ID=38564365

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/010464 WO2007127475A2 (en) 2006-04-28 2007-04-27 Pyridazines for demyelinating diseases and neuropathic pain

Country Status (1)

Country Link
WO (1) WO2007127475A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264014A1 (en) 2001-08-31 2010-12-22 Université Louis Pasteur Substituted pyridazines as anti-inflammatory agents and protein kinase inhibitors
ES2543813T3 (en) 2004-11-02 2015-08-24 Northwestern University Pyridazine compounds for the treatment of inflammatory diseases
EP1812007B1 (en) 2004-11-02 2011-09-07 Northwestern University Pyridazine compounds and methods
CA2650625A1 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
US8158627B2 (en) 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
AU2008225766B2 (en) 2007-03-15 2012-06-07 Novartis Ag Organic compounds and their uses
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AR081626A1 (en) * 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
WO2011137511A1 (en) * 2010-05-05 2011-11-10 Waratah Pharmaceuticals Inc. Compounds, compositions and methods for treatment of central nervous system injuries
WO2011156900A2 (en) * 2010-06-17 2011-12-22 Waratah Pharmaceuticals Inc. Compounds, compositions and methods for treatment of multiple sclerosis
WO2011156901A2 (en) * 2010-06-17 2011-12-22 Waratah Pharmaceuticals Inc. Compounds, compositions and methods for treatment of multiple sclerosis
WO2012012890A1 (en) * 2010-07-28 2012-02-02 Waratah Pharmaceuticals Inc. Compounds, compositions and methods for treatment of arthritis
WO2012012891A1 (en) * 2010-07-29 2012-02-02 Waratah Pharmaceuticals Inc. Compounds, compositions and methods for treatment of arthritis
US9447075B2 (en) 2011-08-02 2016-09-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as EAAT2 activators
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
KR102373700B1 (en) 2014-04-02 2022-03-11 인터뮨, 인크. Anti-fibrotic pyridinones

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0628550A2 (en) * 1993-06-08 1994-12-14 Sterling Winthrop Inc. Pyridazines as interleukin-1beta converting enzyme inhibitors
WO1998046574A1 (en) * 1997-04-16 1998-10-22 Smithkline Beecham Plc Pyridazine and phthalazine derivatives, process of their preparation and their use as anticonvulsants
WO2003047577A2 (en) * 2001-12-06 2003-06-12 Eisai Co Ltd Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses
WO2004046117A1 (en) * 2002-11-19 2004-06-03 Aventis Pharma Deutschland Gmbh Pyridazinone derivatives as gsk-3beta inhibitors
WO2006050389A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods
WO2007127474A2 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0628550A2 (en) * 1993-06-08 1994-12-14 Sterling Winthrop Inc. Pyridazines as interleukin-1beta converting enzyme inhibitors
WO1998046574A1 (en) * 1997-04-16 1998-10-22 Smithkline Beecham Plc Pyridazine and phthalazine derivatives, process of their preparation and their use as anticonvulsants
WO2003047577A2 (en) * 2001-12-06 2003-06-12 Eisai Co Ltd Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses
WO2004046117A1 (en) * 2002-11-19 2004-06-03 Aventis Pharma Deutschland Gmbh Pyridazinone derivatives as gsk-3beta inhibitors
WO2006050389A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods
WO2007127474A2 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ENYEDY I J ET AL: "Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 13, no. 3, 10 February 2003 (2003-02-10), pages 513 - 517, XP008084817, ISSN: 0960-894X *
HU WENHUI ET AL: "Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model", CURRENT ALZHEIMER RESEARCH, BENTHAM SCIENCE PUBLISHERS, NL, vol. 2, no. 2, 1 January 2005 (2005-01-01), pages 197 - 205, XP008084805, ISSN: 1567-2050 *
RANAIVO H R ET AL: "Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 26, no. 2, 11 January 2006 (2006-01-11), pages 662 - 670, XP002457580, ISSN: 0270-6474 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders

Also Published As

Publication number Publication date
WO2007127475A2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
WO2007127475A3 (en) Pyridazines for demyelinating diseases and neuropathic pain
WO2007130474A3 (en) Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
WO2004103208A3 (en) Manufacture and use of implantable reticulated elastomeric matrices
WO2005089502A3 (en) Methods for the treatment of synucleinopathies
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2004019863A3 (en) Combination therapy for treatment of fibrotic disorders
IL225192A (en) Combination of dextromethorphan and quinidine for use in the treatment of mental illness, neuropathic pain or brain injury
SI2527315T1 (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2004100881A3 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
WO2003032994A3 (en) Novel tri-substituted pyrimidines, method for production and use thereof as medicament
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
EP1737453A4 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
AU2003286567A1 (en) Methods for the treatment of skin disorders
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2006058868A3 (en) Substituted pteridines for treating inflammatory diseases
WO2005089504A3 (en) Methods for the treatment of synucleinopathies
WO2005089515A3 (en) Methods for the treatment of synucleinopathies
AU2003300791A1 (en) Combination therapy for the treatment of pain
WO2006055871A3 (en) Treatment for multiple sclerosis
WO2007014943A3 (en) Therapy for neurological diseases
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2005089496A3 (en) Methods for the treatment of synucleinopathies
WO2002064126A3 (en) Method of treating of demyelinating diseases or conditions
WO2007087424A3 (en) Method of treating kcnq related disorders using organozinc compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07776513

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07776513

Country of ref document: EP

Kind code of ref document: A2